<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02494895</url>
  </required_header>
  <id_info>
    <org_study_id>1-2014-0066</org_study_id>
    <nct_id>NCT02494895</nct_id>
  </id_info>
  <brief_title>Ticagrelor Monotherapy After 3 Months in the Patients Treated With New Generation Sirolimus Stent for Acute Coronary Syndrome (TICO Study)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the clinical outcomes of dual antiplatelet therapy with aspirin and ticagrelor vs.
      ticagrelor monotherapy at 3 months after PCI in patients with acute coronary syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major adverse cardiovascular clinical events (MACCE)</measure>
    <time_frame>1 year after the procedure</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>major bleeding</measure>
    <time_frame>1 year after the procedure</time_frame>
    <description>Major bleeding means 1) any intracranial bleeding (excluding microhemorrhages &lt;10 mm evident only on gradient-echo MRI), 2) clinically overt signs of hemorrhage associated with a drop in hemoglobin of ≥5 g/dL or a ≥15% absolute decrease in haematocrit, and 3) fatal bleeding (bleeding that directly results in death within 7 days) in accordance with TIMI Bleeding Criteria.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3056</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Ticagrelor monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ticagrelor monotherapy at 3 months after PCI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ticagrelor with Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ticagrelor with Aspirin DAPT(Dual Anti-platelet Treatment)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor monotherapy</intervention_name>
    <description>Ticagrelor (Brilinta®) is indicated for the prevention of thrombotic events (for example stroke or heart attack) in people with acute coronary syndrome or myocardial infarction with ST elevation. Patients will be randomized to stop aspirin at 3 months after PCI.</description>
    <arm_group_label>Ticagrelor monotherapy</arm_group_label>
    <other_name>Brilinta®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor with Aspirin DAPT(dual antiplatelet treatment)</intervention_name>
    <description>Ticagrelor (Brilinta®) is indicated for the prevention of thrombotic events (for example stroke or heart attack) in people with acute coronary syndrome or myocardial infarction with ST elevation. Patients will be randomized to continue DAPT (aspirin+ticagrelor) up to 1 year.</description>
    <arm_group_label>Ticagrelor with Aspirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients ≥ 19 years old

          -  Patients who received new generation sirolimus-eluting (Osiro®) stent implantation for
             treating ACS

          -  Patients without significant clinical events such as MI, stent thrombosis or
             revascularization until 3 months after PCI

          -  Provision of informed consent

        Exclusion Criteria:

          -  Age &gt; 80 years

          -  Increased risk of bleeding, anemia, thrombocytopenia

          -  A need for oral anticoagulation therapy

          -  Pregnant women or women with potential childbearing

          -  Life expectancy &lt; 1 year

          -  Patients who treated with strong CYP3A4 inhibitors (e.g. ketoconazole, clarithromycin,
             nefazodone, ritonavir, or atazanavir)

          -  Patients who had history of intracranial hemorrhage

          -  Moderate to severe hepatic dysfunction

          -  Increased risk of bradycardia-related symptom (Guidance and reference)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Myeong-Ki Hong, MD, Ph.D</last_name>
    <phone>82-2-2228-8460</phone>
    <email>mkhong61@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MYEONG-KI HONG, MD, Ph.D</last_name>
      <phone>82-2-2228-8460</phone>
      <email>MKHONG61@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2015</study_first_submitted>
  <study_first_submitted_qc>July 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2015</study_first_posted>
  <last_update_submitted>December 29, 2016</last_update_submitted>
  <last_update_submitted_qc>December 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

